Bei Hai Shi

Researchers are evaluating the safety and effectiveness of Henagliflozin in Chinese adults with type 2 diabetes mellitus T2DM. This observational study aims to monitor how this medication impacts metabolic parameters like blood sugar levels, blood pressure, and body weight, as well as its side effects. The study also explores how Henagliflozin affects muscle health, including muscle mass and strength, in real-world use. Participants will receive Henagliflozin as part of their usual care, and the study involves observing these patients without changing their treatment. The main focus is to track adverse events and serious side effects over a 24-week treatment period. Researchers will also assess changes in glycated hemoglobin HbA1c, fasting plasma glucose, post-meal glucose, blood pressure, weight, and muscle health markers during this time. Throughout the 24 weeks, participants will be monitored regularly for safety and treatment effects. Data on adverse events, metabolic changes, and muscle health will be collected to understand the medications impact. The study is sponsored by the Second Affiliated Hospital of Guangxi Medical University and is planned to start in June 2025, with the final results expected by September 2026.